Company Overview
About Paradromics
Paradromics is a neurotechnology company based in Austin, Texas, focused on developing brain-computer interface (BCI) technology specifically for restoring communication and independence to patients with severe paralysis caused by ALS, stroke, and spinal cord injury. The company's lead product, the Connexus BCI, is a fully implantable neural interface system designed to record high-resolution neural signals from the motor cortex and decode them into speech output — enabling patients who have lost the ability to speak or move to communicate through their thoughts.
Business Model & Competitive Advantage
Paradromics has achieved two major regulatory milestones. The FDA granted the company Breakthrough Medical Device Designation for the Connexus system, and in November 2025 awarded an Investigational Device Exemption (IDE) approval for the Connect-One Early Feasibility Study — making Paradromics the first company to receive IDE approval for speech restoration with a fully implantable BCI. In May 2026, the company completed the first successful human implantation of the Connexus BCI at the University of Michigan, entering clinical-stage operations. The company has raised over $105M in total funding, including $88.7M in venture capital across 13 rounds from 28 investors (led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity) plus approximately $18M in grants from the National Institutes of Health (NIH) and DARPA.
Competitive Landscape 2025–2026
Paradromics competes in the emerging BCI space alongside Neuralink (which has implanted more patients but focuses on a broader general-purpose BCI) and Synchron (which uses a minimally invasive endovascular approach). Paradromics differentiates through its focus on high-density neural recording (enabling high-resolution speech decoding) and its clinical regulatory pathway specifically targeting speech restoration.
Key Differentiators
Emerging Innovator
Paradromics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Paradromics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Paradromics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Paradromics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Paradromics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →